Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628999 | 1.00 | CNR2 (0.49) | CNR2TSHRKEAP1DPP4MMP2 | |
| SCHEMBL11835990 | 0.89 | MMP12 (0.63) | TSHRMMP2MMP9MMP12MMP13 | |
| SCHEMBL3489217 | 0.88 | GRIK1 (0.54) | KEAP1PPARGPPARASMN1; SMN2 | |
| SCHEMBL27587469 | 0.84 | ERAP1 (0.49) | CNR2TSHRKEAP1ANPEPERAP1 | |
| SCHEMBL6879395 | 0.82 | TSHR (0.67) | CNR2TSHR | |
| SCHEMBL28033790 | 0.82 | ALDH1A1 (0.47) | MMP2MMP9MMP12MMP13MMP14 | |
| SCHEMBL10779182 | 0.82 | MDM2 (0.52) | CNR2TSHRKEAP1DPP4ANPEP | |
| SCHEMBL27830258 | 0.81 | TAAR1 (0.47) | SMN1; SMN2 | |
| SCHEMBL2291948 | 0.80 | MMP8 (0.56) | CNR2TSHRKEAP1ANPEPERAP1 | |
| SCHEMBL28028204 | 0.80 | CNR2 (0.46) | CNR2TSHRKEAP1ANPEPERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2033635-A1 | Short-chain fatty acid derivatives for treating pruritus | Asan Laboratories Company (Cayman) Limited (CN) | 2009-03-11 | — | — | EP | claimed |
| US-20080107646-A1 | Administering phenylbutyric acid derivative and pharmaceutically acceptable carrier | Sunny Pharmtech Inc. (TW) | 2008-05-08 | — | — | US | claimed |
| US-6403646-B1 | ADMINISTERING PHENYLBUTYRIC ACID OR DERIVATIVES TO TREAT LIVER DISEASE AND EMPHYSEMA CAUSED BY PROTEASE INHIBITOR TYPE Z MUTATION; STIMULATES SECRETION WITHOUT INCREASING SYNTHESIS OF PROTEIN | PERLMUTTER DAVID H (US) | 2002-06-11 | — | — | US | claimed |
| CN-119639276-A | Ink composition, semiconductor nanoparticle-polymer composite prepared therefrom, electronic device, and display device | 三星电子株式会社 | 2025-03-18 | — | — | CN | disclosed |
| US-20230138393-A1 | LINKING AMINO ACID SEQUENCES, MANUFACTURING METHOD THEREOF, AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| WO-2021163467-A1 | LINKING AMINO ACID SEQUENCES, MANUFACTURING METHOD THEREOF, AND USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-08-19 | — | — | WO | disclosed |
| US-8846039-B2 | Method for ameliorating pruritus | ASAN LABORATORIES COMPANY (CAYMAN), LIMITED (TW) | 2014-09-30 | — | — | US | disclosed |
| CN-101218203-B | Fluorinated derivatives of 4- (2-amino-1-hydroxyethyl) phenol as beta 2 adrenoreceptor agonists | ALMIRALL SA | 2012-05-30 | — | — | CN | disclosed |
| CN-101380317-B | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV PHARMACEUTICAL CO LTD | 2010-12-08 | — | — | CN | disclosed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| CN-1425002-A | Pyrrolidine and piperidine derivatives and their use for treatment of neurodegenerative disorders | HOFFMANN LA ROCHE (CH) | 2003-06-18 | — | — | CN | disclosed |
| EP-1278728-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| US-6451819-B2 | PYRROLIDINE-3-YL-SULFANYL, OR SUFONYL OR SUFINYL DERIVATIVES USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-6403646-B1 | ADMINISTERING PHENYLBUTYRIC ACID OR DERIVATIVES TO TREAT LIVER DISEASE AND EMPHYSEMA CAUSED BY PROTEASE INHIBITOR TYPE Z MUTATION; STIMULATES SECRETION WITHOUT INCREASING SYNTHESIS OF PROTEIN | PERLMUTTER DAVID H (US) | 2002-06-11 | — | — | US | disclosed |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | HOFFMANN-LA ROCHE INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
| EP-0295604-A1 | (E)-2-(p-Fluorophenethyl)-3-fluoroallylamine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138393-A1 | LINKING AMINO ACID SEQUENCES, MANUFACTURING METHOD THEREOF, AND USE THEREOF | BCAT2, BCAT1, AARS1 | CNR2 4093/4885TSHR 4518/4885KEAP1 2698/4885 |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | NR1H3, NR1H2, SREBF1 | CNR2 960/4885TSHR 4546/4885KEAP1 57/4885 |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | GRIN1, GRM1, GRIN2B | CNR2 82/4885TSHR 1060/4885KEAP1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.